A rare paraneoplastic condition in Hodgkin lymphoma: Evans syndrome and literature review.

IF 0.9 Q3 MEDICINE, GENERAL & INTERNAL
Northern Clinics of Istanbul Pub Date : 2024-10-03 eCollection Date: 2024-01-01 DOI:10.14744/nci.2022.66742
Unal Atas, Kubra Cerci, Sema Tuncer, Volkan Karakus
{"title":"A rare paraneoplastic condition in Hodgkin lymphoma: Evans syndrome and literature review.","authors":"Unal Atas, Kubra Cerci, Sema Tuncer, Volkan Karakus","doi":"10.14744/nci.2022.66742","DOIUrl":null,"url":null,"abstract":"<p><p>Evans syndrome (ES) is a spectrum of diseases in which the combination of autoimmune hemolytic anemia and immune thrombocytopenia or sometimes neutropenia. ES has been accepted usually as an idiopathic condition, but it may be secondary. The coexistence of autoimmune cytopenias and Hodgkin lymphoma (HL) is rarely observed and the rate of ES in HL patients is not clear. Here we describe a 56-year-old male patient who presented with ES and was diagnosed with HL. After corticosteroids, intravenous immunoglobulin (IVIG) and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) treatment, immune cytopenias were completely resolved. The literature is also reviewed and we found 16 cases in which HL and ES coexist. Although AIHA and immune thrombocytopenia usually develop simultaneously, they rarely occur at different times. Many aspects of the pathogenesis are unknown, but it is thought to be a complex immunological background. Corticosteroids and/or IVIG are the most commonly used first-choice drugs in the initial treatment of ES. Response rates to treatment are variable and response to treatment may be poor, particularly with underlying conditions. If detected, the underlying lymphoma should be treated.</p>","PeriodicalId":19164,"journal":{"name":"Northern Clinics of Istanbul","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11487318/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Northern Clinics of Istanbul","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/nci.2022.66742","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Evans syndrome (ES) is a spectrum of diseases in which the combination of autoimmune hemolytic anemia and immune thrombocytopenia or sometimes neutropenia. ES has been accepted usually as an idiopathic condition, but it may be secondary. The coexistence of autoimmune cytopenias and Hodgkin lymphoma (HL) is rarely observed and the rate of ES in HL patients is not clear. Here we describe a 56-year-old male patient who presented with ES and was diagnosed with HL. After corticosteroids, intravenous immunoglobulin (IVIG) and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) treatment, immune cytopenias were completely resolved. The literature is also reviewed and we found 16 cases in which HL and ES coexist. Although AIHA and immune thrombocytopenia usually develop simultaneously, they rarely occur at different times. Many aspects of the pathogenesis are unknown, but it is thought to be a complex immunological background. Corticosteroids and/or IVIG are the most commonly used first-choice drugs in the initial treatment of ES. Response rates to treatment are variable and response to treatment may be poor, particularly with underlying conditions. If detected, the underlying lymphoma should be treated.

霍奇金淋巴瘤中一种罕见的副肿瘤性疾病:埃文斯综合征和文献综述。
埃文斯综合征(ES)是一种合并自身免疫性溶血性贫血和免疫性血小板减少症(有时为中性粒细胞减少症)的疾病。ES通常被认为是一种特发性疾病,但也可能是继发性的。自身免疫性细胞减少症与霍奇金淋巴瘤(HL)同时存在的情况很少见,而霍奇金淋巴瘤患者的ES发病率也不明确。在此,我们描述了一名 56 岁的男性患者,他出现 ES 并被诊断为 HL。经过皮质类固醇、静脉注射免疫球蛋白(IVIG)和 ABVD(多柔比星、博来霉素、长春新碱、达卡巴嗪)治疗后,免疫性细胞减少症完全消失。我们还查阅了文献,发现有 16 例 HL 和 ES 并存的病例。尽管 AIHA 和免疫性血小板减少症通常同时发生,但它们很少在不同时间出现。发病机制的许多方面尚不清楚,但认为是一种复杂的免疫学背景。皮质类固醇和/或 IVIG 是治疗 ES 最常用的首选药物。对治疗的反应率不尽相同,治疗反应可能较差,尤其是在有基础疾病的情况下。如果发现潜在的淋巴瘤,应进行治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Northern Clinics of Istanbul
Northern Clinics of Istanbul MEDICINE, GENERAL & INTERNAL-
CiteScore
0.40
自引率
0.00%
发文量
48
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信